2025 Q4 -tulosraportti
Vain PDF
59 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 147 | - | - | ||
| 1 000 | - | - | ||
| 450 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·2 t sittenJust heard the mentioned podcast… It made me, if possible, even more optimistic!! Even though it's in Norwegian😅 I'm Danish, so I had to prick up my ears a bit. This case here is simply too amazing, and thanks to everyone who contributes with info etc.🙌 Huge upside!!!
·5 t sittenFORGET "TYPICAL CEO". LET'S TALK ABOUT WHAT ERIK WIKLUND ACTUALLY DID. 🧬👑 Most biotech CEOs do one of two things: they pitch an idea they got, or they inherit a company someone else built. Wiklund did something almost no one does. He took a company that was almost dead — old Targovax, a cancer vaccine story about to run out of both money and faith — and rebuilt it. From the molecule up. Not with a borrowed idea. With science he himself helped discover. Think about how rare that is. He's not just the scientist who understands the technology at a cellular level. He's not just the McKinsey strategist who understands business and deals. He's not just the operator who has lived through a European billion-exit. He is all three. Simultaneously. In one person. Most companies get one of the three cards. Circio got the whole hand. The chairman called the turnaround "remarkable". It's not flattering PR — it's a precise description of raising a company and rebuilding it around the technology of the future. You don't back an idea when you own Circio. You back a man who has already proven he can build something real out of almost nothing. We know what we own. ♟️🧱🍷
·5 t sittenHas anyone had the money debited for the subscriptions you made on vps.no?
·5 t sitten · MuokattuHave you heard about CD98hc? Transmembrane glycoprotein. It functions as a highly effective molecular shuttle across the blood-brain barrier (BBB), allowing next-generation biotherapeutics and drugs to reach the central nervous system with high, sustained concentrations. Eli Lilly is heavily investing in such "brain shuttle" technology. November 17, 2025, approximately 1 week before the agreement Circio entered into with a big pharma in the central nervous system (CNS) field, Lilly entered into a massive development agreement worth up to $2.6 billion with the South Korean biotech company ABL Bio. ABL Bio is world-renowned for its "Grabody-B" platform, which specializes in bispecific antibodies specifically for crossing the blood-brain barrier. Eli Lilly uses and explores RNA technology in combination with central nervous system delivery mechanisms. RNA is the "cargo" – CD98hc is the "ferry". Lilly uses advanced RNA technology to measure the effect of its CD98hc projects. By sequencing RNA in single cells, they were able to precisely prove which brain cells (neurons, astrocytes, or endothelial cells) actually took up the medicine via the CD98hc shuttle. Lilly uses advanced antibody shuttles targeting CD98hc precisely to solve the biggest problem in modern medicine: Getting their new, powerful RNA-based medicines safely into the brain. Neurodegenerative diseases - Alzheimer's disease etc.·4 t sittenWhich company has the most cutting-edge DNA/ cirkulerRNA technology and a deal with an unknown big Pharma in CNS?
·19 t sittenWhat's next here? Any important dates? or just rockets
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
59 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sittenJust heard the mentioned podcast… It made me, if possible, even more optimistic!! Even though it's in Norwegian😅 I'm Danish, so I had to prick up my ears a bit. This case here is simply too amazing, and thanks to everyone who contributes with info etc.🙌 Huge upside!!!
- ·5 t sittenFORGET "TYPICAL CEO". LET'S TALK ABOUT WHAT ERIK WIKLUND ACTUALLY DID. 🧬👑 Most biotech CEOs do one of two things: they pitch an idea they got, or they inherit a company someone else built. Wiklund did something almost no one does. He took a company that was almost dead — old Targovax, a cancer vaccine story about to run out of both money and faith — and rebuilt it. From the molecule up. Not with a borrowed idea. With science he himself helped discover. Think about how rare that is. He's not just the scientist who understands the technology at a cellular level. He's not just the McKinsey strategist who understands business and deals. He's not just the operator who has lived through a European billion-exit. He is all three. Simultaneously. In one person. Most companies get one of the three cards. Circio got the whole hand. The chairman called the turnaround "remarkable". It's not flattering PR — it's a precise description of raising a company and rebuilding it around the technology of the future. You don't back an idea when you own Circio. You back a man who has already proven he can build something real out of almost nothing. We know what we own. ♟️🧱🍷
- ·5 t sittenHas anyone had the money debited for the subscriptions you made on vps.no?
- ·5 t sitten · MuokattuHave you heard about CD98hc? Transmembrane glycoprotein. It functions as a highly effective molecular shuttle across the blood-brain barrier (BBB), allowing next-generation biotherapeutics and drugs to reach the central nervous system with high, sustained concentrations. Eli Lilly is heavily investing in such "brain shuttle" technology. November 17, 2025, approximately 1 week before the agreement Circio entered into with a big pharma in the central nervous system (CNS) field, Lilly entered into a massive development agreement worth up to $2.6 billion with the South Korean biotech company ABL Bio. ABL Bio is world-renowned for its "Grabody-B" platform, which specializes in bispecific antibodies specifically for crossing the blood-brain barrier. Eli Lilly uses and explores RNA technology in combination with central nervous system delivery mechanisms. RNA is the "cargo" – CD98hc is the "ferry". Lilly uses advanced RNA technology to measure the effect of its CD98hc projects. By sequencing RNA in single cells, they were able to precisely prove which brain cells (neurons, astrocytes, or endothelial cells) actually took up the medicine via the CD98hc shuttle. Lilly uses advanced antibody shuttles targeting CD98hc precisely to solve the biggest problem in modern medicine: Getting their new, powerful RNA-based medicines safely into the brain. Neurodegenerative diseases - Alzheimer's disease etc.·4 t sittenWhich company has the most cutting-edge DNA/ cirkulerRNA technology and a deal with an unknown big Pharma in CNS?
- ·19 t sittenWhat's next here? Any important dates? or just rockets
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 147 | - | - | ||
| 1 000 | - | - | ||
| 450 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
59 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sittenJust heard the mentioned podcast… It made me, if possible, even more optimistic!! Even though it's in Norwegian😅 I'm Danish, so I had to prick up my ears a bit. This case here is simply too amazing, and thanks to everyone who contributes with info etc.🙌 Huge upside!!!
- ·5 t sittenFORGET "TYPICAL CEO". LET'S TALK ABOUT WHAT ERIK WIKLUND ACTUALLY DID. 🧬👑 Most biotech CEOs do one of two things: they pitch an idea they got, or they inherit a company someone else built. Wiklund did something almost no one does. He took a company that was almost dead — old Targovax, a cancer vaccine story about to run out of both money and faith — and rebuilt it. From the molecule up. Not with a borrowed idea. With science he himself helped discover. Think about how rare that is. He's not just the scientist who understands the technology at a cellular level. He's not just the McKinsey strategist who understands business and deals. He's not just the operator who has lived through a European billion-exit. He is all three. Simultaneously. In one person. Most companies get one of the three cards. Circio got the whole hand. The chairman called the turnaround "remarkable". It's not flattering PR — it's a precise description of raising a company and rebuilding it around the technology of the future. You don't back an idea when you own Circio. You back a man who has already proven he can build something real out of almost nothing. We know what we own. ♟️🧱🍷
- ·5 t sittenHas anyone had the money debited for the subscriptions you made on vps.no?
- ·5 t sitten · MuokattuHave you heard about CD98hc? Transmembrane glycoprotein. It functions as a highly effective molecular shuttle across the blood-brain barrier (BBB), allowing next-generation biotherapeutics and drugs to reach the central nervous system with high, sustained concentrations. Eli Lilly is heavily investing in such "brain shuttle" technology. November 17, 2025, approximately 1 week before the agreement Circio entered into with a big pharma in the central nervous system (CNS) field, Lilly entered into a massive development agreement worth up to $2.6 billion with the South Korean biotech company ABL Bio. ABL Bio is world-renowned for its "Grabody-B" platform, which specializes in bispecific antibodies specifically for crossing the blood-brain barrier. Eli Lilly uses and explores RNA technology in combination with central nervous system delivery mechanisms. RNA is the "cargo" – CD98hc is the "ferry". Lilly uses advanced RNA technology to measure the effect of its CD98hc projects. By sequencing RNA in single cells, they were able to precisely prove which brain cells (neurons, astrocytes, or endothelial cells) actually took up the medicine via the CD98hc shuttle. Lilly uses advanced antibody shuttles targeting CD98hc precisely to solve the biggest problem in modern medicine: Getting their new, powerful RNA-based medicines safely into the brain. Neurodegenerative diseases - Alzheimer's disease etc.·4 t sittenWhich company has the most cutting-edge DNA/ cirkulerRNA technology and a deal with an unknown big Pharma in CNS?
- ·19 t sittenWhat's next here? Any important dates? or just rockets
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 147 | - | - | ||
| 1 000 | - | - | ||
| 450 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt